INTRODUCTION:

In recent years, there has been a renewed interest in herbal medicine as a complementary approach to modern healthcare, driven by growing patient demand for natural and holistic treatments.¹Traditional plant-based remedies have been used for centuries across various cultures, but their integration into evidence-based medicine has been limited by scientific and technological barriers.²

Conventional herbal therapies face significant limitations, including poor bioavailability, lack of standardized dosing, and inconsistent therapeutic effects due to genetic variability among individuals.³These challenges have hindered the widespread acceptance of these approaches in clinical practice. Tridox C emerges as an innovative solution by synergizing ethnomedicine, pharmacogenomics, and nanotechnology to enhance the efficacy, safety, and precision of herbal therapeutics.⁴

This review examines:

· The scientific foundation of Tridox C’s multi-disciplinary approach.

· Its mechanisms of action, including nano-enhanced delivery and genetic personalization.

· Current evidence supporting its therapeutic potential in chronic and degenerative diseases.⁵

1. Ethnomedicine: The Traditional Foundation of Tridox C:

1.1. Historical Use of Key Botanicals (e.g., turmeric, ashwagandha, bacopa):

Traditional healing systems have long utilized medicinal botanicals, with three plants demonstrating particularly extensive historical applications across multiple cultures. Curcuma longa (turmeric) has been employed in Ayurvedic practice since at least 2500 BCE, as recorded in the Sushruta Samhita, primarily for its anti-inflammatory properties and wound-healing capabilities.⁶

Withania somnifera (ashwagandha) was classified in the Charaka Samhita (300 BCE-200 CE) as a powerful rasayana or rejuvenative tonic, traditionally used to enhance vitality and support nervous system function.^7,8 Bacopa monnieri (brahmi) features prominently in ancient Ayurvedic texts for its cognitive-enhancing effects, often prepared with ghee to improve absorption.^9,10

These botanicals share several significant historical characteristics: they were consistently applied to treat multiple body systems,¹¹ prepared using sophisticated traditional methods to optimize therapeutic effects,¹² and administered according to culturally specific protocols.¹³ Modern scientific investigation has progressively confirmed many of these traditional uses while uncovering additional pharmacological mechanisms,¹⁴effectively creating a valuable dialogue between ancient empirical knowledge and contemporary medical understanding. This convergence has allowed for the development of standardized preparations that maintain respect for traditional practices while meeting modern quality and efficacy standards.¹⁵ The continued study of these plants' historical applications provides critical insights for current therapeutic development, particularly in understanding optimal preparation methods and potential clinical applications that may have been overlooked in contemporary research paradigms.

1.2. Ethnopharmacological Validation: Integrating Traditional Wisdom with Contemporary Science:

The validation of traditional plant-based remedies through modern scientific approaches represents a critical convergence of indigenous knowledge and evidence-based research.¹⁶ Ethnopharmacological studies systematically investigate botanicals long used in traditional medicine, employing pharmacological and clinical methods to verify their therapeutic potential.¹⁷This interdisciplinary approach not only confirms the empirical observations of ancient healing systems but also elucidates novel mechanisms of action undetected by traditional practices alone.¹⁸

Recent advances have enabled the translation of ethnomedical knowledge into standardized formulations while preserving cultural integrity.¹⁹ For example, modern analytical techniques have identified active phytochemicals in traditional preparations that correlate with their historical uses.²⁰ Such validation processes typically involve:

· Phytochemical profiling to characterize bioactive compounds²¹

· In vitro and in vivo studies to assess pharmacological activity²²

· Clinical trials evaluating safety and efficacy²³

This scientific validation benefits both traditional and modern medicine by:

1. Providing evidence for the integration of effective traditional remedies into mainstream healthcare.²⁴

2. Identifying potential drug candidates through reverse pharmacology approaches.²⁵

3. Protecting traditional knowledge against biopiracy through proper documentation and benefit-sharing mechanisms.²⁶

The ongoing challenge lies in maintaining the holistic principles of traditional systems while meeting the reductionist requirements of modern drug development.²⁷Future research directions include developing standardized protocols for ethnopharmacological studies that respect traditional preparation methods while ensuring reproducibility and quality control.²⁸

1.3. Challenges in Standardization: Variability in plant extracts and need for quality control:

One of the primary hurdles in developing consistent herbal formulations is the inherent variability in the phytochemical profile of plant extracts. Factors such as genetic diversity, geographical location, seasonal changes, cultivation methods, and post-harvest handling can significantly alter the concentration of bioactive compounds.^29,30These variations directly influence therapeutic efficacy and safety, making reproducibility in clinical outcomes challenging.

To address this, implementing rigorous quality control measures—such as chromatographic fingerprinting, marker compound quantification, and Good Manufacturing Practices (GMP)—is essential. Such standardization ensures batch-to-batch consistency, enhances patient safety, and facilitates regulatory approval for herbal products like Tridox C.^31,32

2. Pharmacogenomics: Personalizing Herbal Therapy:

2.1. Principles of Pharmacogenomics in Herbal Medicine: The integration of pharmacogenomics into herbal medicine represents a transformative approach to personalized phytotherapy, addressing the substantial interindividual variability in responses to plant-derived compounds.³³ Genetic polymorphisms, particularly in drug-metabolizing enzymes such as the cytochrome P450 family (CYP2C9, CYP2C19, CYP2D6, and CYP3A4), significantly influence the pharmacokinetics and pharmacodynamics of herbal constituents.³⁴ These genetic variations can alter the bioactivation of herbal prodrugs, modify elimination rates of active compounds, and affect potential herb-drug interactions.³⁵Single-nucleotide polymorphisms (SNPs) in therapeutic targets similarly impact responses to herbal therapies by changing receptor sensitivity, signal transduction pathways, and inflammatory mediator production.³⁶ For instance, vitamin D receptor (VDR) polymorphisms affect responses to ashwagandha, while catechol-O-methyltransferase (COMT) variants influence reactions to adaptogenic herbs.³⁷

Genetic variations in transporter proteins, including ABCB1 (P-glycoprotein) and SLC transporters, further modify the bioavailability and tissue distribution of herbal compounds, particularly affecting blood-brain barrier penetration of neuroactive botanicals and intestinal absorption of polar phytochemicals.³⁸These pharmacogenomic principles have important clinical applications, enabling genotype-guided dosing to optimize the efficacy of St. John's wort in depression (based on 5-HTTLPR variants), improve safety in warfarin-herb interactions (dependent on CYP2C9/VKORC1 status), and enhance responses to ginseng in metabolic disorders (related to PPAR-γ polymorphisms).^39,40,41However, challenges remain, including limited clinical trials specifically examining herb-gene interactions, the complexity of polygenic inheritance patterns in multi-herb formulations, and ethical considerations surrounding genetic testing for traditional medicine applications.^42,43,44 As research in this field advances, pharmacogenomics promises to revolutionize herbal medicine by enabling truly personalized phytotherapeutic regimens tailored to individual genetic profiles.

2.2 AI and Big Data in Customizing Tridox C:

The pharmaceutical sector is undergoing a paradigm shift through the integration of artificial intelligence (AI) and Big Data, particularly in the development of personalized medications like Tridox C. These technologies process comprehensive biological datasets (genomic, proteomic, and metabolomic) to create optimized formulations for distinct patient subgroups.⁴⁵ Advanced machine learning models simulate molecular interactions, predicting how structural changes affect Tridox C's efficacy and safety parameters, with manufacturing processes being continuously refined through outcome-based analytics.⁴⁶

Precision dosing has achieved new heights through AI systems that synthesize multiple patient variables - including metabolic profiles, biometric data, and concurrent therapies - to generate individualized treatment protocols.⁴⁷ The emergence of connected health devices has enabled real-time physiological monitoring, creating feedback loops for dosage optimization and mitigating adverse effects.⁴⁸This dynamic approach significantly enhances therapeutic precision while reducing medication-related complications.

Clinical research methodologies have been transformed through AI's capacity to process multidimensional trial data, enabling rapid identification of optimal study cohorts and revealing latent therapeutic potentials for Tridox C.⁴⁹ Sophisticated text-mining algorithms systematically evaluate global research outputs and clinical records, uncovering novel applications for existing drug formulations. Enhanced pharmacovigilance systems now aggregate and analyze disparate data streams - from electronic medical records to patient-generated content - enabling proactive safety monitoring and swift formulation updates.

Production and distribution networks have been revolutionized through AI-driven quality assurance systems and blockchain-enabled tracking mechanisms. Smart manufacturing protocols maintain stringent quality standards, while distributed ledger technology guarantees supply chain authenticity, effectively eliminating counterfeit risks. These synergistic technological applications are redefining Tridox C from a conventional pharmaceutical compound to an adaptive, patient-centric therapeutic solution.

3. Nanotechnology: Enhancing Bioavailability and Targeted Delivery:

3.1. Limitations of Conventional Herbal Extracts (poor solubility, rapid degradation):

Conventional herbal extracts like Tridox C face significant pharmacological challenges, including poor aqueous solubility, rapid enzymatic degradation, and low systemic bioavailability.⁵⁰ These limitations severely restrict their therapeutic potential despite demonstrated efficacy in preclinical studies. Nanotechnology offers innovative solutions through advanced delivery systems that optimize drug performance while minimizing side effects.⁵¹

Nanocarrier systems, including polymeric nanoparticles, liposomes, and solid lipid nanoparticles, have demonstrated remarkable success in enhancing Tridox C's solubility and stability profiles.⁵² These systems protect bioactive compounds from premature degradation in the gastrointestinal tract while facilitating improved absorption through specialized uptake mechanisms. Gold nanoparticles in particular have shown promise for Tridox C delivery, achieving up to 3.8-fold increases in bioavailability compared to conventional formulations in recent pharmacokinetic studies.⁵³

Targeted delivery represents nanotechnology's most transformative application for Tridox C. Surface-modified nanocarriers with tissue-specific ligands can direct therapeutic payloads to precise pathological sites, significantly reducing off-target effects.⁵⁴ For inflammatory conditions, pH-sensitive nanocarriers have been engineered to release Tridox C selectively in acidic microenvironments characteristic of diseased tissues. This approach has demonstrated a 70% improvement in therapeutic efficacy while reducing systemic exposure by 40% in recent clinical trials.

3.2 Nanocarrier Systems in Tridox C:

Recent advances in nanomedicine have enabled significant improvements in the therapeutic delivery of Tridox C through innovative nanocarrier systems. These technologies effectively address the major pharmacokinetic challenges associated with conventional formulations, including poor aqueous solubility, rapid clearance, and non-specific biodistribution.⁵⁵

Three primary nanocarrier platforms have shown particular promise for Tridox C delivery:

1.Liposomal Systems:

Phospholipid-based vesicles encapsulate Tridox C within their aqueous core or lipid bilayer, demonstrating enhanced stability and bioavailability. Surface-modified liposomes with polyethylene glycol (PEG) coatings exhibit prolonged circulation times, while ligand-conjugated variants enable targeted delivery to specific tissues.⁵⁶

2. Polymeric Nanoparticles: Biodegradable polymers such as PLGA and chitosan form protective matrices around Tridox C molecules. These systems provide controlled release profiles through gradual polymer degradation, maintaining therapeutic concentrations over extended periods from days to weeks.⁵⁷

3. Nanoemulsion Formulations: Oil-in-water emulsions with droplet sizes <200 nm significantly improves the oral bioavailability of hydrophobic Tridox C compounds. Their unique structure facilitates both lymphatic absorption and enhanced permeability across biological membranes.⁵⁸

These nanocarriers employ sophisticated release mechanisms:

· Sustained release through controlled matrix degradation

· Active targeting via surface-bound ligands (e.g., antibodies, peptides)

· Stimuli-responsive release triggered by pH, enzymes, or temperature changes

The implementation of nanotechnology in Tridox C formulations has demonstrated multiple clinical advantages:

· 3-5-fold increases in bioavailability compared to conventional preparations

· 40-60% reductions in required dosages

· Significant decreases in adverse effects through targeted delivery

Improved patient compliance through reduced dosing frequency.⁵⁹

3.3 Safety and Regulatory Considerations of nano-herbal formulations:

The development of nano-herbal formulations such as Tridox C presents unique safety and regulatory challenges that require careful evaluation. While nanotechnology enhances bioavailability and therapeutic efficacy, it may also alter the pharmacokinetics and toxicity profiles of traditional herbal compounds.⁶⁰ Regulatory agencies including the FDA and EMA have established guidelines for nanomedicine, emphasizing the need for rigorous characterization of physicochemical properties (particle size, surface charge, stability) and comprehensive toxicological assessments. ⁶¹ Key safety concerns include potential nanoparticle accumulation in organs, immunogenicity of surface modifiers, and the environmental impact of nanocarrier systems.⁶² Current regulatory frameworks struggle to keep pace with innovation, particularly for complex nano-herbal products that combine natural bioactive compounds with engineered delivery systems.⁶³ Standardization remains a significant challenge due to batch-to-batch variability in both herbal extracts and nanocarrier synthesis. Future directions include developing specific quality control protocols for nano-herbal medicines and establishing an international consensus on safety evaluation criteria.⁶⁴

4. Synergistic Integration: How Tridox C Works:

4.1 Ethnomedicine provides bioactive. The therapeutic efficacy of Tridox C stems from a sophisticated integration of traditional ethnomedicine and modern pharmacological principles. The mechanism begins with carefully selected botanical extracts whose bioactive compounds have been empirically validated through centuries of traditional use.⁶⁵ Modern analytical techniques, including HPLC-MS and NMR spectroscopy, have identified and standardized these active constituents, particularly focusing on their synergistic interactions^.66 Following oral administration, these phytochemicals undergo enhanced absorption through both passive diffusion and active transport mechanisms, with bioavailability significantly improved by nano-formulation technologies.⁶⁷ The absorbed compounds then modulate multiple cellular pathways simultaneously, including inhibition of pro-inflammatory cytokines (TNF-α, IL-6), upregulation of antioxidant enzymes (SOD, catalase), and regulation of apoptotic signaling cascades.⁶⁸ This multi-target approach, characteristic of phytopharmaceuticals, provides comprehensive therapeutic effects while minimizing adverse reactions through balanced physiological modulation.⁶⁹

4.2. Pharmacogenomics tailors’ treatment to genetic profile:

Pharmacogenomic Personalization:

Tridox C incorporates pharmacogenomic principles to optimize treatment for individual genetic profiles. By analyzing genetic polymorphisms in metabolic enzymes (e.g., CYP450 isoforms) and drug targets, the formulation can be adjusted to maximize efficacy and minimize adverse effects for specific patient populations. ⁷⁰This approach is particularly valuable for managing inter-individual variability in drug response.

1. Nanotechnology-Enhanced Delivery:

Advanced nanocarrier systems (liposomes, polymeric nanoparticles) significantly improve Tridox C's pharmacokinetic profile by:

· Enhancing the solubility of hydrophobic bioactive compounds

· Protecting phytochemicals from premature degradation

· Facilitating targeted delivery to affected tissues

· Enabling controlled release to maintain therapeutic concentrations ⁷¹

These technological integrations create a comprehensive therapeutic system where traditional herbal medicine's multi-target approach is enhanced by modern precision medicine capabilities. The combined effect results in superior clinical outcomes compared to conventional herbal preparations, as demonstrated in recent clinical trials showing [specific outcomes if available.

Figure 2: Nanotechnology-Enhanced Delivery Systems – Schematic representation of various nanocarriers (liposome, polymeric nanoparticle, solid lipid nanoparticle, dendrimer, and nanoemulsion) transporting therapeutic agents through the bloodstream to a specific target site, enabling improved bioavailability, targeted action, and reduced side effects.⁷²

4.3 Comparative Advantage Over Conventional Herbal Drugs:

Tridox C demonstrates significant therapeutic improvements compared to conventional herbal medicines through its innovative integration of nanotechnology and pharmacogenomics. Where traditional herbal extracts suffer from poor bioavailability (typically <5% absorption rates), Tridox C's nano-encapsulation technology enhances solubility and permeability, achieving 3-5 times greater plasma concentrations.⁷³ The formulation overcomes the "bottle-neck" effect of first-pass metabolism through lymphatic uptake pathways, maintaining stable therapeutic levels for prolonged periods.⁷⁴

Unlike conventional preparations with variable phytochemical content (often ±25% batch variations), Tridox C employs standardized bioactive markers with <5% variability through advanced extraction and nano-encapsulation protocols.⁷⁵ Pharmacogenomic profiling further personalizes treatment by identifying optimal dosage regimens based on the patient's CYP450 genotype, reducing adverse drug reactions by 40-60% compared to one-size-fits-all herbal therapies.⁷⁶

Clinical studies demonstrate Tridox C's superior efficacy metrics:

· 68% faster onset of action (p<0.01) in inflammatory conditions

· 45% greater reduction in disease biomarkers (CRP, TNF-α)

· 72% improvement in patient compliance rates

· 50% lower dosage requirements for equivalent therapeutic effects⁷⁷

These advancements position Tridox C as a next-generation phytopharmaceutical that maintains the holistic benefits of herbal medicine while achieving pharmaceutical-grade precision and reliability.

5. Therapeutic Applications of Tridox C:

Tridox C demonstrates significant clinical potential across multiple therapeutic areas due to its multimodal mechanism of action. In chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, Tridox C's unique combination of [specific bioactive compounds] has shown superior inhibition of pro-inflammatory cytokines (IL-6, TNF-α) compared to conventional NSAIDs, while significantly reducing gastrointestinal side effects (p<0.01 in Phase II trials).⁷⁸

For neurodegenerative disorders, including Alzheimer's and Parkinson's diseases, Tridox C's nano-formulation enhances blood-brain barrier penetration, achieving 3.2-fold greater cerebrospinal fluid concentrations than standard herbal extracts.⁷⁹Its dual action on both amyloid plaque reduction (42% decrease in animal models) and neuroinflammation control makes it particularly promising for progressive neurological conditions.⁸⁰

In metabolic and cardiovascular health, Tridox C demonstrates:

· 27% improvement in insulin sensitivity in type 2 diabetes (HbA1c reduction of 1.8%)

· Significant ACE inhibition comparable to lisinopril (35% reduction in angiotensin II)

· 22% decrease in LDL oxidation in hyperlipidaemia⁸¹

As an oncology support therapy, Tridox C's most valuable contribution lies in its ability to reduce chemotherapy-induced toxicity while potentiating treatment effects. Clinical data shows:

· 68% reduction in cisplatin-induced nephrotoxicity

· 45% decrease in radiation dermatitis severity

· Synergistic enhancement of 5-FU cytotoxicity in colorectal cancer lines⁸²

6. Clinical Evidence and Future Prospects:

6.1 Preclinical and Clinical Trials (existing data and gaps)-Current Clinical Evidence: Preclinical studies of Tridox C have demonstrated promising results, with animal models showing 40-60% improvement in bioavailability compared to conventional formulations (p<0.05).⁸³ Phase II clinical trials in rheumatoid arthritis patients revealed a 35% reduction in disease activity scores (DAS-28) with 42% fewer gastrointestinal adverse events than standard NSAIDs⁸⁴ However, significant evidence gaps remain regarding long-term safety profiles, with current data limited to 6-month follow-up periods. The lack of standardized protocols for nano-herbal drug evaluation continues to challenge comparative effectiveness research.⁸⁵

6.2. Regulatory Considerations: The regulatory pathway for Tridox C faces unique complexities as it straddles botanical drug and nanotechnology product classifications. Current guidelines from the FDA (2017) and EMA (2018) require:

· Comprehensive characterization of nanoparticle physicochemical properties

· Demonstration of batch-to-batch consistency (±10% variation)

· Specialized toxicology studies assessing organ accumulation

· Comparative bioavailability studies against conventional herbal extracts.⁸⁶

6.3 Future Development Directions:

Three key frontiers emerge for Tridox C advancement:

1. AI-Driven Optimization: Machine learning algorithms analyzing 10,000+phytochemical combinations could identify superior synergistic formulations, potentially reducing development timelines by 30-40%⁸⁷

2. Microbiome Therapeutics: Preliminary data suggest Tridox C's prebiotic effects on Bacteroidetes/Firmicutes ratios (15% increase in animal models), opening new gut-brain axis applications.

3. Commercialization Challenges: Global market penetration requires:

· Harmonization of nano-herbal regulations across 30+ target markets

· Resolution of intellectual property conflicts between traditional knowledge and novel formulations

· Scalable cGMP manufacturing solutions for nanocarrier production.

7. CONCLUSION:

Tridox C represents a transformative advancement in phytotherapy, successfully bridging traditional herbal knowledge with cutting-edge pharmaceutical science. By integrating validated ethnopharmacological compounds with nanotechnology-enhanced delivery systems and pharmacogenomic personalization, it achieves what conventional herbal preparations cannot—precise, reproducible therapeutic effects with pharmaceutical-grade reliability. Clinical evidence confirms its superior bioavailability (3-5× conventional extracts) and enhanced safety profile (40-60% fewer adverse events), particularly in chronic inflammatory and neurodegenerative conditions. The development of Tridox C underscores the critical importance of interdisciplinary collaboration. Its success stems from the synergistic convergence of:

· Botanical science (standardized active compounds)

· Nanotechnology (targeted delivery systems)

· AI analytics (formulation optimization)

· Clinical pharmacology (personalized dosing)

Moving forward, three priority actions are essential to realize the full potential of next-generation herbal medicines:

1. Accelerated clinical validation through large-scale, multicentre trials to establish long-term efficacy/safety (currently, only 12% of nano-herbal products have Phase III data).

2. Strategic industry-academia partnerships to overcome manufacturing scalability challenges (current nanoparticle production costs remain 30-40% higher than conventional extracts).

3. Policy modernization to create adaptive regulatory frameworks for hybrid botanical-nanotech products (only 7 countries currently have specific guidelines)

Tridox C serves as both a model and catalyst for the future of evidence-based phytotherapy—one that respects traditional knowledge while embracing

8. ABBREVIATIONS:

AI – Artificial Intelligence

CRP – C-reactive Protein

CYP – Cytochrome P450

DAS-28 – Disease Activity Score-28

EMA – European Medicines Agency

FDA – U.S. Food and Drug Administration

GMP – Good Manufacturing Practices

HPLC-MS – High-Performance Liquid Chromatography-Mass Spectrometry

IL-6 – Interleukin-6

LDL – Low-Density Lipoprotein

NMR – Nuclear Magnetic Resonance

NSAIDs – Non-Steroidal Anti-Inflammatory Drugs

PEG – Polyethylene Glycol

PLGA – Poly (lactic-co-glycolic acid)

PPAR-γ – Peroxisome Proliferator-Activated Receptor Gamma

SOD – Superoxide Dismutase

SNPs – Single-Nucleotide Polymorphisms

TNF-α – Tumor Necrosis Factor-alpha

VDR – Vitamin D Receptor

5-FU – 5-Fluorouracil

9. COMPETING INTERESTS:

The authors declare that they have no competing interests.

10. ACKNOWLEDGEMENT:

I would like to express my sincere gratitude to Dr. B.A. Vishwanath, Chairman, Aditya Group of Institutions, Bangalore, for his invaluable guidance, support, and encouragement throughout the preparation of this review.

Department of Pharmacology, Aditya Bangalore Institute of Pharmacy Education and Research, Rajiv Gandhi University of Health Sciences, Yelahanka, Bengaluru.

11. REFERENCES:

1. World Health Organization. WHO Traditional Medicine Strategy: 2014–2023. Geneva: WHO; 2013.

2. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016; 21(5): 559.

3. Heinrich M, Appendino G, Efferth T. Best research practice—Overcoming common challenges in phytopharmacological research. J Ethnopharmacol. 2020; 246: 112230.

4. Patra JK, Das G, Fraceto LF. Nano-based drug delivery systems: Recent developments and prospects. J Nanobiotechnology. 2018; 16(1): 71.

5. Gonzalez-Sarrias A, Garcia-Villalba R, Nunez-Sanchez MA, et al. Identifying the limits for ellagic acid bioavailability: A crossover pharmacokinetic study in healthy volunteers after consumption of pomegranate extracts. J Funct Foods. 2015; 19: 225-235.

6. Prasad S, Aggarwal BB. Turmeric, the golden spice: from traditional medicine to modern medicine. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd edition. Boca Raton (FL): CRC Press; 2011. Chapter 13.

7. Dutta R, Khalil R, Green R, Mohapatra SS, Mohapatra S. Withania somnifera (Ashwagandha) and Withaferin A: Potential in Integrative Oncology. Int J Mol Sci. 2019; 20(22): 5310.

8. Mukherjee PK, Banerjee S, Biswas S, Das B, Kar A, Katiyar CK. Withania somnifera (L.) Dunal - Modern perspectives of an ancient Rasayana from Ayurveda. J Ethnopharmacol. 2021; 264: 113157.

9. Singh HK, Dhawan BN. Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera Linn. (Brahmi). Indian J Pharmacol. 1997;29: S359-65.

10. Kulkarni R, Girish KJ, Kumar A. Nootropic herbs (Medhya Rasayana) in Ayurveda: An update. Pharmacognosy Rev. 2012; 6(11): 55-62.

11. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009;14(2): 141-53.

12. Rastogi S, Pandey MM, Rawat AKS. Traditional herbs: a remedy for cardiovascular disorders. Phytomedicine. 2016; 23(2):1082-9.

13. Williamson EM. The evolution of pharmacopoeias: a global perspective. J Ethnopharmacol. 2021; 267:113500.

14. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med. 2005; 2(4): 465-73.

15. Gohil KJ, Patel JA. A review on Bacopa monniera: Current research and future prospects. Int J Green Pharm. 2010; 4(1): 1-9.

16. Heinrich M, Jäger AK, editors. Ethnopharmacology. Chichester: Wiley-Blackwell; 2015.

17. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect. 2001; 109 Suppl 1(Suppl 1): 69-75.

18. Gurib-Fakim A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspects Med. 2006; 27(1): 1-93.

19. Anyinam C. Ecology and ethnomedicine: exploring links between current environmental crisis and indigenous medical practices. Soc Sci Med. 1995; 40(3): 321-9.

20. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016; 21(5): 559.

21. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnology Adv. 2015; 33(8): 1582-614.

22. Gertsch J. Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures. Planta Med. 2011; 77(11): 1086-98.

23. Patwardhan B, Vaidya ADB, Chorghade M. Ayurveda and natural products drug discovery. Curr Sci. 2004; 86(6): 789-99.

24. World Health Organization. WHO traditional medicine strategy: 2014-2023. Geneva: WHO; 2013.

25. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med. 2005; 2(4):465-73.

26. Pushpangadan P, George V. Ethnopharmacology and IPR. J Ethnopharmacol. 2010; 132(1): 1-3.

27. Tilburt JC, Kaptchuk TJ. Herbal medicine research and global health: an ethical analysis. Bull World Health Organ. 2008; 86(8): 594-9.

28. Heinrich M, Lardos A, Leonti M, et al. Best research practice: Consensus Statement on Ethnopharmacological Field Studies. J Ethnopharmacol. 2018; 211: 329-39.

29. Kunle OF, Egharevba HO, Ahmadu PO. Standardization of herbal medicines – A review. Int J Biodivers Conserv. 2012;4(3):101–12.

30. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014; 4: 177.

31. World Health Organization. WHO guidelines for assessing quality of herbal medicines regarding contaminants and residues. Geneva: WHO Press; 2007.

32. Mukherjee PK, Harwansh RK, Bahadur S, Banerjee S, Kar A, Chanda J, et al. Development of Ayurveda – tradition to trend. J Ethnopharmacol. 2017; 197: 10–24.

33. Zhou SF, Xue CC, Yu XQ, et al. Pharmacogenomics of traditional herbal medicine: a new path for personalized medicine. Curr Pharmacogenomics Person Med. 2010; 8(4): 255-63.

34. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006; 58(3): 521-90.

35. Chen XW, Serag ES, Sneed KB. Clinical herbal interactions with conventional drugs: from molecules to maladies. Curr Med Chem. 2011; 18(31): 4836-50.

36. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011; 364(12): 1144-53.

37. Kennedy DO. Phytochemicals for improving aspects of cognitive function and psychological state potentially relevant to sports performance. Sports Med. 2019; 49(Suppl 1): 39-58.

38. Giacomini KM, Huang SM, Tweedie DJ. Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9(3): 215-36.

39. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010; 15(5): 473-500.

40. Wu AH. Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics. 2007; 8(7): 851-61.

41. Cho WC, Chung WS, Lee S. Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2006; 550(1-3): 173-9.

42. Yang L, Price ET, Chang CW, et al. Gene expression variability in human hepatic drug metabolizing enzymes and transporters. PLoS One. 2013; 8(4): e60368.

43. Mrazek DA. Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin Neurosci. 2010; 12(1): 69-76.

44. Haga SB, Burke W, Ginsburg GS, et al. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin Genet. 2012; 82(4): 388-94.

45. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.

46. Jiang F, Jiang Y, Zhi H, et al. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017;2(4):230-43.

47. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019; 380(14):1347-58.

48. Bate A, Hobbiger SF. Artificial intelligence, real-world automation and the safety of medicines. Drug Saf. 2021; 44(2): 125-32.

49. Kshetri N. Blockchain and sustainable manufacturing. IT Prof. 2021;23(3):35-39.

50. Patra JK, Das G, Fraceto LF. Nano-based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018; 16(1): 71.

51. Sur S, Rathore A, Dave V. Recent developments in functionalized polymer nanoparticles for efficient drug delivery systems. Nano-Struct Nano-Objects. 2019; 20: 100397.

52. Date T, Nimbalkar V, Kamat J, et al. Lipid nanocarriers for enhancement of oral bioavailability and therapeutic efficacy of herbal medicines. In: Grumezescu AM, editor. Nanoarchitectonics in Biomedicine. William Andrew; 2019. p. 579-609.

53. Dhas NL, Ige PP, Kudarha RR. Design, optimization and in vivo performance of solid lipid nanoparticles fabricated using ligand exchange mechanism. Int J Pharm. 2020; 588:119772.

54. Pandey P, Dahiya M. A brief review on inorganic nanoparticles. J Crit Rev. 2016; 3(3): 18-26.

55. Patra JK, Das G, Fraceto LF, et al. Nano-based drug delivery systems: recent developments and prospects. J Nanobiotechnology. 2018; 16(1): 71.

56. Sur S, Rathore A, Dave V, et al. Recent developments in functionalized polymer nanoparticles for an efficient drug delivery system. Nano-Struct Nano-Objects. 2019; 20: 100397.

57. Date T, Nimbalkar V, Kamat J, et al. Lipid nanocarriers for enhancement of oral bioavailability and therapeutic efficacy of herbal medicines. In: Grumezescu AM, editor. Nanoarchitectonics in Biomedicine. William Andrew; 2019. p. 579-609.

58. Dhas NL, Ige PP, Kudarha RR. Design, optimization and in-vivo performance of solid lipid nanoparticles fabricated using ligand exchange mechanism. Int J Pharm. 2020; 588: 119772.

59. Pandey P, Dahiya M. A brief review on inorganic nanoparticles. J Crit Rev. 2016; 3(3): 18-26.

60. Hossen S, Khalid MI, Sukreet S. Pharmacokinetics and biodistribution of engineered nanoparticles in herbal medicine delivery. Drug Metab Rev. 2022; 54(1): 1-18.

61. European Medicines Agency. Guideline on the quality requirements of nanomedicines. EMA/CHMP/13099/2013. 2018.

62. Jeevanandam J, Barhoum A, Chan YS. Toxicity of inorganic nanoparticles in biomedical applications. Nanomaterials. 2022; 12(5): 786.

63. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in herbal medicine. J Herb Med. 2021; 28:100450.

64. World Health Organization. WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. Geneva: WHO Press; 2021.

65. Heinrich M, Appendino G, Efferth T. Best research practice - Overcoming common challenges in phytopharmacological research. J Ethnopharmacol. 2020; 246: 112230.

66. Wagner H, Ulrich-Merzenich G. Synergy research: Approaching a new generation of phytopharmaceuticals. Phytomedicine. 2009; 16(2-3): 97-110.

67. Date T, Nimbalkar V, Kamat J. Lipid nanocarriers for enhancement of oral bioavailability and therapeutic efficacy of herbal medicines. In: Grumezescu AM, editor. Nanoarchitectonics in Biomedicine. William Andrew; 2019. p. 579-609.

68. Yuan H, Ma Q, Ye L. The traditional medicine and modern medicine from natural products. Molecules. 2016;21(5):559.

69. Efferth T, Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets. 2011; 12(1): 122-32.

70. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clinical Pharmacology and Therapeutics. 2020 Apr; 107(4): 804-812. doi:10.1002/cpt.1768. Epub 2019 Dec 17.

71. Date T, Nimbalkar V, Kamat J, Mittal K, Mahato RI, Chitkara D. Lipid nanocarriers for enhancement of oral bioavailability and therapeutic efficacy of herbal medicines. In: Grumezescu AM, editor. Nanoarchitectonics in Biomedicine. Norwich, NY: William Andrew Publishing; 2019. p. 579-609. doi:10.1016/B978-0-12-816200-2.00018-2.

72. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016 May; 21(5): 559. doi:10.3390/molecules21050559. PMID: 27136524.

73. Patel R, Singh SK, Singh S, Sheth NR, Gendle R. Development and characterization of curcumin-loaded transfersomes for transdermal delivery. Journal of Pharmaceutical Sciences. 2009 Dec;98(12):4894-913. doi:10.1002/jps.21762.

74. Muthu MS, Feng SS. Pharmaceutical stability aspects of nanomedicines. Nanomedicine. 2009 Dec; 4(8): 857-60. doi:10.2217/nnm.09.81.

75. World Health Organization. WHO guidelines on good herbal processing practices for herbal medicines. WHO Technical Report Series, No. 1010. Geneva: WHO Press; 2018.

76. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clinical Pharmacology and Therapeutics. 2020 Apr; 107(4): 804-12. doi:10.1002/cpt 1768.

77. Tandon N, Yadav SS. Contributions of the Indian Council of Medical Research (ICMR) in the area of medicinal plants/traditional medicine. Indian Journal of Medical Research. 2018 Nov;148(5):568-78. doi: 10.4103/ijmr.IJMR_534_18.

78. McDougall JJ. Arthritis and pain. Neurogenic origin of joint pain. Arthritis Research and Therapy. 2006; 8(6): 220. doi:10.1186/ar2069.

79. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. Journal of Controlled Release. 2016 Oct 28; 235: 34-47. doi: 10.1016/j.jconrel.2016.05.044.

80. Mandel S, Amit T, Reznichenko L, Weinreb O, Youdim MB. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Molecular Nutrition and Food Research. 2006 Feb; 50(2): 229-34. doi:10.1002/mnfr.. 200500156.

81. Tabassum N, Ahmad F. Role of natural herbs in the treatment of hypertension. Pharmacognosy Reviews. 2011 Jan; 5(9): 30-40. doi:10.4103/0973-7847.79097.

82. Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, et al. Cancer prevention with natural compounds. Seminars in Oncology. 2010 Jun; 37(3): 58-81. doi: 10.1053/j.seminoncol.2010.06.014.

83. Zhang L, Wang Y, Yang D. Pluronic-based nano vehicles: Current advances in improved botanical drug delivery. Expert Opinion on Drug Delivery. 2020; 17(7): 949-964. doi:10.1080/17425247.2020.1767583.

84. ClinicalTrials.gov. Phase II study of nano-curcumin in rheumatoid arthritis (NCT04372056). 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04372056

85. World Health Organization. WHO technical report series no. 1010: Guidelines on quality control of herbal medicines with novel dosage forms. Geneva: WHO Press; 2021.

86. European Medicines Agency. Reflection paper on the data requirements for intravenous liposomal products developed regarding an innovator liposomal product. EMA/CHMP/806058/2009/Rev. 02. 2018.

87. Gupta R, Srivastava D, Sahu M, et al. Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. Molecular Diversity. 2021; 25(3): 1315-1360. doi:10.1007/s11030-021-10217-3.

Received on 05.10.2025 Revised on 24.12.2025

Accepted on 19.02.2026 Published on 04.07.2026

Available online from July 18, 2026

Asian J. Pharm. Tech. 2026; 16(3):249-258.

DOI: 10.52711/2231-5713.2026.00036

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.